Fresenius Kabi Launches Stimufend (biosimilar, pegfilgrastim) for Febrile Neutropenia in the US
- The company reported the commercial availability of Stimufend, a biosimilar to Neulasta in the US for patients who are at risk for febrile neutropenia. Stimufend is commercially available in a 6mg/0.6 mL solution in a single-dose pre-filled syringe combined with a passive needle guard
- Stimufend was approved in the US in Sept 2022 for non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. The FDA approval of Stimufend was based on the totality of evidence supporting its biosimilarity to Neulasta
- The company launched pegfilgrastim biosimilar in a prefilled syringe in France in Oct 2022, following the EC's marketing authorization in Mar 2022
Ref: Businesswire | Image: Fresenius Kabi
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.